We are live on
!
Find out more
JJ
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter
Est. Return
+2.02%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$51.6M
(-13%)
Cap. Flow
-$47.1M
Cap. Flow
% of AUM
-13.85%
Top 10 Holdings %
Top 10 Hldgs %
92.17%
Holding
22
New
–
Increased
–
Reduced
2
Closed
–
Avg Time Held
1
year
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$40.9M |
| 2 |
Procept Biorobotics
PRCT
|
+$6.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$232M
| $75.7M | 22.28% |
3,379,064
| – | – |
2021 Q3
4 quarters
|
|
2
Legend Biotech
LEGN
$3.7B
| $66.5M | 19.56% |
1,629,173
| – | – |
2021 Q3
4 quarters
|
|
|
3
Procept Biorobotics
PRCT
$1B
| $35.8M | 10.54% |
863,908
-154,570
| -15% | -$6.17M |
2021 Q3
4 quarters
|
|
4
CVRx
CVRX
$35.7M
| $32.6M | 9.6% |
3,495,575
| – | – |
2021 Q3
4 quarters
|
|
5
MeiraGTx Holdings
MGTX
$904M
| $24.4M | 7.17% |
2,898,550
| – | – |
2021 Q3
4 quarters
|
|
6
Protagonist Therapeutics
PTGX
$8.82B
| $20.6M | 6.08% |
2,449,183
| – | – |
2021 Q3
4 quarters
|
|
7
Xencor
XNCR
$1.74B
| $19.4M | 5.72% |
748,062
| – | – |
2021 Q4
3 quarters
|
|
8
DELISTED
Cue Health Inc. Common Stock
HLTH
| $16.7M | 4.91% |
5,548,864
| – | – |
2021 Q3
4 quarters
|
|
9
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $11M | 3.25% |
3,670,516
| – | – |
2021 Q3
4 quarters
|
|
10
Adicet Bio
ACET
$45.8M
| $10.4M | 3.05% |
45,559
| – | – |
2021 Q3
4 quarters
|
|
|
11
Arrowhead Research
ARWR
$8.25B
| $8.18M | 2.41% |
247,598
-1,013,271
| -80% | -$40.9M |
2021 Q3
4 quarters
|
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $7.73M | 2.27% |
1,000,000
| – | – |
2021 Q3
4 quarters
|
|
13
Vor Biopharma
VOR
$1.11B
| $4.28M | 1.26% |
53,733
| – | – |
2021 Q3
4 quarters
|
|
14
Nano X Imaging
NNOX
$40.1M
| $2.21M | 0.65% |
192,429
| – | – |
2021 Q4
3 quarters
|
|
15
Aldeyra Therapeutics
ALDX
$47.7M
| $2.11M | 0.62% |
394,834
| – | – |
2021 Q3
4 quarters
|
|
|
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $815K | 0.24% |
281,052
| – | – |
2021 Q3
4 quarters
|
|
|
HLSQ
17
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
| $725K | 0.21% |
1,123
| – | – |
2021 Q3
4 quarters
|
|
|
PHAS
18
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $283K | 0.08% |
1,607,044
| – | – |
2021 Q3
4 quarters
|
|
|
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $140K | 0.04% |
4,200
| – | – |
2021 Q3
4 quarters
|
|
20
Senseonics Holdings Inc
SENS
$428M
| $72K | 0.02% |
2,731
| – | – |
2021 Q3
4 quarters
|
|
21
CalciMedica
CALC
$7.31M
| $47K | 0.01% |
708
| – | – |
2021 Q3
4 quarters
|
|
22
Gyre Therapeutics
GYRE
$686M
| $34K | 0.01% |
8,927
| – | – |
2021 Q3
4 quarters
|
|
Similar funds
SEM
TI
GIM
QCMNJ
LOPW
HW
CCM
LWM
Johnson & Johnson's Q3 2022 Portfolio in Review
As of Q3 2022, Johnson & Johnson held 22 positions worth $340M, down 13% from $391M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Johnson & Johnson withdrew a net $47.1M in Q3 2022, reducing 2 holdings. Its largest reduction was Arrowhead Research, cutting an estimated $40.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Johnson & Johnson's biggest Q3 2022 reduction was Arrowhead Research, cutting an estimated $40.9M.
- Johnson & Johnson's ten largest holdings make up 92% of its $340M portfolio in Q3 2022.
- Johnson & Johnson opened 0 new positions and closed 0 in Q3 2022.
- Johnson & Johnson's portfolio value fell 13% quarter-over-quarter to $340M.
Based on Johnson & Johnson's 13F filing for Q3 2022, filed 10 Nov 2022.